Computed Tomogram prior to Prostatectomy

Höcht, Stefan; Wiegel, Thomas; Bottke, Dirk; Jentsch, Hilmar; Sternemann, M.; Rosenthal, Peter; Hinkelbein, W.

doi:10.1007/s00066-002-0896-9

Cited by 6 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accurate localization of prostate cancer paves the way for innovative, minimally invasive therapies and it may be possible to reduce the number of men undergoing biopsy or to improve the diagnostic yield of prostate biopsies by including an imaging method in the diagnostic workup [30]. Despite considerable advances in technology, prostate cancer cannot be reliably detected by current conventional imaging modalities such as TRUS and CT [31, 32]. However, MRI at high field strength may provide improved detection of localized disease and more accurate local staging, which may enable focal therapy in the near future.…”

Section: Mrimentioning

confidence: 99%

Imaging Prostate Cancer: An Update on Positron Emission Tomography and Magnetic Resonance Imaging

et al. 2010

View full text Add to dashboard Cite

Prostate cancer is a common cancer in men and continues to be a major health problem. Imaging plays an essential role in the clinical management of patients. An important goal for prostate cancer imaging is more accurate disease characterization through the synthesis of anatomic, functional, and molecular imaging information. Developments in imaging technologies, specifically magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT), have improved the detection rate of prostate cancer. MRI has improved lesion detection and local staging. Furthermore, MRI allows functional assessment with techniques such as diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI. The most common PET radiotracer, 18F-fluorodeoxyglucose, is not very useful in prostate cancer. However, in recent years other PET tracers have improved the accuracy of PET/CT imaging of prostate cancer. Among these, choline (labeled with 18F or 11C), 11C-acetate, and 18F-fluoride have demonstrated promising results, and other new radiopharmaceuticals are currently under evaluation in preclinical and clinical studies.

show abstract

Section: Mrimentioning

confidence: 99%